Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
For the nine months, revenue was INR 12,925 million compared to INR 10,591.27 million a year ago. Net income was INR 3,167.4 million compared to INR 3,258.17 million a year ago. Basic earnings per share from continuing operations was INR 23.29 compared to INR 23.98 a year ago. Diluted earnings per share from continuing operations was INR 23.28 compared to INR 23.97 a year ago.